GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies

Clinical trial NCT03214666 · TERMINATED

Trial details

NCT number: NCT03214666
Sponsor: GT Biopharma, Inc.
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

High-risk Myelodysplastic Syndromes Acute Myelogenous Leukemia Systemic Mastocytosis Mast Cell Leukemia

Start date: 2020-01-01
Primary completion: 2021-08-02
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.